Combined Anabolic Therapy

Description

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

Conditions

Osteoporosis, Postmenopausal, Osteoporosis

Talk to us

Study Overview

On this page

Study Details

Study overview

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

Combined Anabolic Therapy Study

Combined Anabolic Therapy

Condition
Osteoporosis, Postmenopausal
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * women aged 45+
  • * postmenopausal
  • * osteoporotic with high risk of fracture
  • * no significant previous use of bone health modifying treatments
  • * known congenital or acquired bone disease other than osteoporosis
  • * significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease
  • * abnormal calcium or parathyroid hormone level
  • * serum vitamin D \<20 ng/dL
  • * anemia (hematocrit \<32%)
  • * history of malignancy (except non-melanoma skin carcinoma)
  • * excessive alcohol use or substance abuse
  • * known contraindications to romosozumab or teriparatide

Ages Eligible for Study

45 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Massachusetts General Hospital,

Benjamin Leder, MD, PRINCIPAL_INVESTIGATOR, MGH

Study Record Dates

2027-07-01